

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Evolution of frontline treatment of diffuse large... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-1933/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-1933" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update" />
    
            <meta name="og:title" content="F1000Research Article: Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.">
            <meta name="og:description" content="Read the latest article version by Jung Yong Hong, Cheolwon Suh, Won Seog Kim, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="9460">
            <meta name="article-id" content="8790">
            <meta name="dc.title" content="Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update">
            <meta name="dc.description" content="Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.">
            <meta name="dc.subject" content="">
            <meta name="dc.creator" content="Hong, Jung Yong">
            <meta name="dc.creator" content="Suh, Cheolwon">
            <meta name="dc.creator" content="Kim, Won Seog">
            <meta name="dc.date" content="2016/08/08">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.8790.1">
            <meta name="dc.source" content="F1000Research 2016 5:1933">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/08/08">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="1933">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.8790.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-1933">
            <meta name="citation_title" content="Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update">
            <meta name="citation_abstract" content="Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.">
            <meta name="citation_description" content="Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.">
            <meta name="citation_keywords" content="">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jung Yong Hong">
            <meta name="citation_author_institution" content="Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, South Korea">
            <meta name="citation_author" content="Cheolwon Suh">
            <meta name="citation_author_institution" content="Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, South Korea">
            <meta name="citation_author" content="Won Seog Kim">
            <meta name="citation_author_institution" content="Division of Hematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University, Seoul, 135-710, South Korea">
            <meta name="citation_publication_date" content="2016/08/08">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="1933">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.8790.1">
            <meta name="citation_firstpage" content="1933">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-1933/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-1933.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=9460 /> <input type=hidden id=articleId name=articleId value=8790 /> <input type=hidden id=xmlUrl value="/articles/5-1933/v1/xml"/> <input type=hidden id=xmlFileName value="-5-1933-v1.xml"> <input type=hidden id=article_uuid value=21acf028-966b-4baf-9a51-51a6ff45d3c5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.8790.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.8790.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-1933"
  },
  "headline": "Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update",
  "datePublished": "2016-08-08T14:25:32",
  "dateModified": "2016-08-08T14:25:32",
  "author": [
    {
      "@type": "Person",
      "name": "Jung Yong Hong"
    },    {
      "@type": "Person",
      "name": "Cheolwon Suh"
    },    {
      "@type": "Person",
      "name": "Won Seog Kim"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-1933.html",
            "name": "Evolution of frontline treatment of diffuse large B-cell lymphoma:..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Evolution of frontline treatment of diffuse large B-cell lymphoma:... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=9460 data-id=8790 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8790.1" data-recommended="" data-doi="10.12688/f1000research.8790.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-1933/v1/pdf?article_uuid=21acf028-966b-4baf-9a51-51a6ff45d3c5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-8790-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-8790-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-8790-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Hong JY, Suh C and Kim WS. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1933 (<a class=new-orange href="https://doi.org/10.12688/f1000research.8790.1" target=_blank>https://doi.org/10.12688/f1000research.8790.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-8790-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=8790 id=track-article-signin-8790 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8790?target=/articles/5-1933.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9460 /> <input name=articleId type=hidden value=8790 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jung Yong Hong<sup>1</sup>,&nbsp;</span><span class="">Cheolwon Suh<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:wskimsmc@skku.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Won Seog Kim</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jung Yong Hong<sup>1</sup>,&nbsp;</span><span class="">Cheolwon Suh<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:wskimsmc@skku.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Won Seog Kim</span></a><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 08 Aug 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.8790.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, South Korea<br/> <sup>2</sup> Division of Hematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University, Seoul, 135-710, South Korea<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=9545-15548></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16474-15549></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Won Seog Kim (<a href="mailto:wskimsmc@skku.edu">wskimsmc@skku.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Won Seog Kim </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> All authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2016 Hong JY <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Hong JY, Suh C and Kim WS. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1933 (<a href="https://doi.org/10.12688/f1000research.8790.1" target=_blank>https://doi.org/10.12688/f1000research.8790.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 08 Aug 2016, <b>5</b>(F1000 Faculty Rev):1933 (<a href="https://doi.org/10.12688/f1000research.8790.1" target=_blank>https://doi.org/10.12688/f1000research.8790.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 08 Aug 2016, <b>5</b>(F1000 Faculty Rev):1933 (<a href="https://doi.org/10.12688/f1000research.8790.1" target=_blank>https://doi.org/10.12688/f1000research.8790.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d71867e176>Introduction</h2><p class="" id=d71867e179>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Therapeutic advances have been achieved in DLBCL with the addition of the anti-CD20 monoclonal antibody rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Despite this, about one-third of patients with DLBCL do not achieve durable remission and develop relapsed/refractory disease<sup><a href="#ref-3">3</a></sup>. Various strategies have been implemented to improve the outcomes of DLBCL. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the development of more effective chemotherapy platforms and on subtype-specific therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d71867e196>Toward more effective chemotherapy platforms beyond R-CHOP</h2><div class=section><a name=d71867e199 class=n-a></a><h3 class=section-title>R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)</h3><p class="" id=d71867e204>The Groupe d'Etude des Lymphomes de l'Adulte investigated increased dose-intensity approaches to improve on R-CHOP. They showed that intensified immunochemotherapy with R-ACVBP significantly improved the survival of patients<sup><a href="#ref-4">4</a></sup>. The primary endpoint was event-free survival (EFS). After a median follow-up of 44 months, 3-year estimates of EFS were 81% (95% confidence interval [CI] 7586) in the R-ACVBP group and 67% (95% CI 5973) in the R-CHOP group (hazard ratio [HR] 0.56, 95% CI 0.380.83, P=0.0035). Three-year overall survival (OS) (92% [8795] versus 84% [7789], HR 0.44 [0.280.81], P=0.0071) was also increased in the R-ACVBP group. The R-ACVBP group showed significantly increased but manageable grade 34 hematological toxicities, with a proportion of febrile neutropenia of 38% (75/196) compared with 9% (16/183) in the R-CHOP group<sup><a href="#ref-4">4</a></sup>. However, we should interpret these positive results for R-ACVBP with caution for the following reasons. First, some of the drugs in the regimen are not available in all countries and testing of substitute drugs or modifications would be needed in real-world practice. Second, the inclusion criteria were limited to patients 1859 years old and to patients with an age-adjusted international prognostic index (IPI) of 1. These inclusion criteria are not really applicable for the majority of patients with DLBCL. R-ACVBP was the first intensified multidrug regimen to improve on R-CHOP as a first-line treatment for DLBCL in a randomized phase III trial and R-ACVBP should be strongly considered in a substantial proportion of fit patients with curable DLBCL. However, the drawbacks mentioned above restrict its potential as a universal first-line platform for DLBCL treatment.</p></div><div class=section><a name=d71867e216 class=n-a></a><h3 class=section-title>DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab)</h3><p class="" id=d71867e221>Several international groups investigated another increased dose-intensity regimen, DA-EPOCH-R<sup><a href="#ref-5">5</a><a href="#ref-7">7</a></sup>. The National Cancer Institute group showed that the progression-free survival (PFS) and OS at 5 years were 79% and 80%, respectively, and suggested that DA-EPOCH-R was a promising first-line treatment for DLBCL, especially in low- and intermediate-IPI groups<sup><a href="#ref-5">5</a></sup>. The Cancer and Leukemia Group B reported that time to progression (TTP) and OS rates were 81% and 84% at 5-years, respectively, with a median follow-up of 62 months and showed that DA-EPOCH-R provided highly durable remissions in both germinal center B-cell (GCB) and non-GCB subtypes<sup><a href="#ref-6">6</a></sup>. Most recently, the Spanish Programa Espaol de Tratamientos en Hematologa group reported 10-year follow-up data showing a good long-term outcome and a tolerable toxicity profile of DA-EPOCH-R in high-risk large B-cell lymphoma patients (IPI higher than 2 or age-adjusted IPI higher than 1)<sup><a href="#ref-7">7</a></sup>. Based on these promising results and favorable toxicity profiles, a randomized phase III study comparing DA-EPOCH-R with R-CHOP (NCT00118209) has completed patient recruitment. The primary endpoint is EFS and results are pending.</p></div><div class=section><a name=d71867e244 class=n-a></a><h3 class=section-title>Optimization of rituximab administration</h3><p class="" id=d71867e249>Further intensification of chemotherapy may not be feasible in older patients, so further intensification of rituximab appears to be an attractive strategy because of its wide therapeutic window. The Deutsche Studiengruppe Hochmaligne Non-Hodgkin Lymphome (DSHNHL) group assumed that early dose densification of rituximab in combination with CHOP-14 might be beneficial and tested a schedule of administration of 375 mg/m<sup>2</sup> rituximab on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85, and 99, combined with six cycles of CHOP-14, comparing this with eight 2-week applications of rituximab plus the same chemotherapy schedule (DENSE-R-CHOP-14 trial). Unfortunately, although dose-dense rituximab achieved higher rituximab serum levels, it was not more effective than eight 2-week applications, even though there were minor improvements in outcomes for male patients with a poor prognosis<sup><a href="#ref-8">8</a></sup>. The DSHNHL group also tested whether prolonged rituximab exposure might improve the efficacy of R-CHOP. They administered 375 mg/m<sup>2</sup> rituximab on days -4, 0, 10, 29, 57, 99, 155, and 239, together with six cycles of R-CHOP-14 (SMARTE-R-CHOP-14 trial). Interestingly, they reported that compared with eight 2-week applications, extended rituximab exposure significantly improved the outcomes of older poor-prognosis patients without increasing toxicities<sup><a href="#ref-9">9</a></sup>. The superiority of the SMARTE-R approach will be tested in an ongoing phase III trial using an optimized schedule of rituximab and liposomal vincristine (OPTIMAL&gt;60 trial, NCT01478542) and the primary endpoint of the study is PFS. In previous trials of DLBCL, elderly male patients demonstrated significantly lower rituximab serum levels and worse outcomes than those in elderly female patients. The randomized phase II SEXIE-R-CHOP-14 trial was designed to test the administration of increased doses of rituximab in elderly male patients with DLBCL<sup><a href="#ref-10">10</a></sup>. Increasing rituximab dose from 375 mg/m<sup>2</sup> to 500 mg/m<sup>2</sup> eliminated the increased risk of elderly male patients, showing that PFS rates after a period of 3 years were 74% in males and 68% in females (P=0.396) and the 3-year OS rates were 82% and 72%, respectively (P=0.111)<sup><a href="#ref-10">10</a></sup>. In terms of maintenance therapy, a recent large multicenter phase III trial (NHL13 trial) including 662 DLBCL patients showed that rituximab maintenance therapy during the first remission does not significantly alter the outcome for patients, showing that 3-year estimates of EFS (the primary endpoint) at 3 years is 80% for rituximab maintenance versus 77% for observation (HR 0.79 [0.571.08], P=0.1433) and OS also remains unchanged (92% versus 90%)<sup><a href="#ref-11">11</a></sup>. However, 10% EFS and PFS benefit of rituximab maintenance in subgroup analysis of male patients appears to be worthy of further investigation.</p></div><div class=section><a name=d71867e286 class=n-a></a><h3 class=section-title>Obinutuzumab-CHOP</h3><p class="" id=d71867e291>Obinutuzumab (GA101), a new, humanized, monoclonal type II anti-CD20 antibody modified by glycoengineering, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>. Obinutuzumab had an acceptable and manageable safety profile. A phase II trial (GATHER) of obinutuzumab plus CHOP (G-CHOP) as first-line chemotherapy for untreated CD20+ DLBCL suggested that G-CHOP could be a safe and effective regimen and showed the dose intensity of CHOP was maintained throughout treatment<sup><a href="#ref-14">14</a></sup>. The study demonstrated that the ORR was 83% (complete response [CR] 55% [44/80], partial response [PR] 28% [22/80]) and PFS/OS were not fully evaluated due to a short follow-up period. Now, a randomized phase III study (GOYA, NCT01287741) comparing G-CHOP with R-CHOP as first-line treatment for DLBCL has completed patient recruitment and results are pending. The primary endpoint of the study is PFS and the results are being watched with keen interest to see whether G-CHOP can replace R-CHOP as a new universal first-line platform for DLBCL treatment.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d71867e309>Toward subtype-specific therapy, the first step to precision medicine</h2><div class=section><a name=d71867e312 class=n-a></a><h3 class=section-title>Cell-of-origin in DLBCL</h3><p class="" id=d71867e317>DLBCL is a heterogeneous disease with a variety of clinical presentations. Gene expression profiling (GEP) has classified DLBCL into different molecular cell-of-origin (COO) subtypes: GCB, activated B-cell (ABC), and primary mediastinal B-cell (PMB) lymphoma and a minority of unclassified DLBCL<sup><a href="#ref-15">15</a></sup>. DLBCL COO subtypes have distinct pathobiology and show striking differences in clinical outcomes, with the ABC subtype being associated with the worst outcomes<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. BCL2-driven malignant transformation is one of the principal pathophysiological mechanisms of GCB-subtype DLBCL, and constitutive activation of the NF-B pathway is the hallmark of ABC-subtype DLBCL<sup><a href="#ref-15">15</a><a href="#ref-17">17</a></sup>.</p><p class="" id=d71867e338>The gold standard method to assign COO relies on the detection of intact RNA using fresh-frozen tissue (e.g. Lymphochip microarray or Affymetrix array). These are the most accurate methods, but their high cost and long turnaround time, and the limitations in the availability of patient samples (fresh-frozen tissue only), make these platforms impractical for routine use in practice. Considerable efforts have been made to approximate the results of this gold-standard method using practical technology platforms<sup><a href="#ref-18">18</a></sup>.</p><p class="" id=d71867e345><b><i>Immunohistochemistry-based assays.</i></b> Hans <i>et al</i>. suggested using an immunohistochemistry (IHC)-based COO assignment algorithm comprising CD10, BCL6, and MUM1 but showed only 79% concordance with cDNA microarray<sup><a href="#ref-19">19</a></sup>. Since then, a number of other IHC-based COO assignment algorithms have been developed, named after their proposers Choi, Tally, Visco, Colomo, and Muris<sup><a href="#ref-18">18</a></sup>. However, their concordance rate is unsatisfactory, and Gutierrez <i>et al</i>. reported disappointing results, which showed that the proportion of cases misclassified by IHC-based approaches ranges from 30% to 60% and that none of the IHC-based algorithms detected prognostic differences between GCB and non-GCB subtypes of DLBCL<sup><a href="#ref-20">20</a></sup>. Until now, IHC-based approaches were widely used in the United States and worldwide. However, these approaches have their limitations, as mentioned above.</p><p class="" id=d71867e369><b><i>GEP-based assays using formalin-fixed paraffin-embedded tissue.</i></b> Recently, technologies have been developed that allow GEP using the fragmented RNA derived from formalin-fixed paraffin-embedded tissue (FFPET). The major two platforms are cDNA-mediated annealing, selection, extension, and ligation (DASL) and NanoString (Lymph2Cx assay)<sup><a href="#ref-21">21</a><a href="#ref-23">23</a></sup>. Recent reports have shown robust results with the GEP-based technique using the Lymph2Cx assay, with a high concordance (&gt;95%) between independent laboratories and significant prognostic value according COO<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Lymph2Cx is also the first GEP-based assay to demonstrate consistent interlaboratory performance. Considering its rapid turnaround time, accuracy, and the convenience of using FFPET, it is hoped that diverse GEP-based assays using FFPET will provide more uniform and consistent assignment of COO in DLBCL, such as Lymph2Cx assay, quantitative nuclease protection assay, ICEPlex<sup></sup> system, massive parallel quantitative RT-PCR, and reverse transcriptase multiplex ligation-dependent probe amplification assay<sup><a href="#ref-25">25</a><a href="#ref-28">28</a></sup>.</p></div><div class=section><a name=d71867e400 class=n-a></a><h3 class=section-title>ABC-subtype DLBCL</h3><p class="" id=d71867e405>ABC-subtype DLBCL is characterized by chronic active BCR signaling, constitutive MYD88 signaling, and subsequent NF-B pathway, AKT/mTOR pathway, and interferon pathway activation<sup><a href="#ref-15">15</a><a href="#ref-17">17</a>,<a href="#ref-29">29</a></sup>. The ABC subtype is associated with the worst outcome among COO subtypes of DLBCL when treated with standard R-CHOP chemotherapy. Therefore, the majority of clinical trials of novel agents in combination with R-CHOP as front-line treatment of DLBCL that are currently underway are specifically targeting the ABC subtype of DLBCL.</p><p class="" id=d71867e418><b><i>Ibrutinib plus R-CHOP.</i></b> Constitutively activated signaling through BCR and its associated protein tyrosine kinases (such as Brutons tyrosine kinase [BTK]) play a crucial role in the development and survival of malignant B-cells, including having involvement in the pathogenesis of the ABC subtype of DLBCL<sup><a href="#ref-29">29</a></sup>. A phase 1/2 trial of ibrutinib (BTK inhibitor) has shown selective activity against ABC-subtype DLBCL<sup><a href="#ref-30">30</a></sup>. A phase Ib trial of ibrutinib plus R-CHOP showed that ibrutinib and R-CHOP did not affect each others pharmacokinetics, that ibrutinib is well tolerated when added to R-CHOP, and that all 18 patients with DLBCL who received the recommended phase 2 dose had an overall response<sup><a href="#ref-31">31</a></sup>. Based on these data, a randomized, double-blind, phase III trial (PHOENIX, NCT01855750) comparing ibrutinib plus R-CHOP with placebo plus R-CHOP in newly diagnosed non-GCB-subtype DLBCL has completed patient recruitment. The primary endpoint of the study is EFS and the results are pending.</p><p class="" id=d71867e436><b><i>Lenalidomide plus R-CHOP.</i></b> Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity plus indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, including B-, T-, natural killer, and dendritic cells<sup><a href="#ref-32">32</a></sup>. The antineoplastic effects of lenalidomide in ABC-subtype DLBCL were associated with direct targeting of IRF-4, leading to downregulation of NF-B pathway activity and augmentation of the interferon pathway<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. Recently, the results of two phase II trials of lenalidomide plus R-CHOP in DLBCL were published. An Italian group (REAL07 trial) reported an overall response rate (ORR) of 92% (CR 86%, PR 6%) and 2-year PFS and OS rates of 80% (95% CI 6489) and 92% (95% CI 7997), respectively<sup><a href="#ref-34">34</a></sup>. The Mayo Clinic also demonstrated that the ORR was 98% (59 of 60), with 80% (48 of 60) achieving CR, and EFS and OS rates at 24 months were 59% (95% CI 4874) and 78% (95% CI 6890), respectively. Notably, the study revealed that lenalidomide combined with R-CHOP overcame the negative prognostic impact of a non-GCB phenotype, showing no difference in 24-month PFS or OS for lenalidomide plus R-CHOP patients on the basis of non-GCB and GCB subtype (60% versus 59% [P=0.83] and 83% versus 75% [P=0.61] at 2 years)<sup><a href="#ref-35">35</a></sup>. Based on these data, a randomized, double-blind, phase III trial (ROBUST, NCT02285062) comparing lenalidomide plus R-CHOP versus placebo plus R-CHOP in newly diagnosed ABC-subtype DLBCL defined by central GEP assay (Lymph2Cx) is open and is actively recruiting. The primary endpoint of the ROBUST trial is EFS.</p><p class="" id=d71867e461><b><i>Bortezomib plus R-CHOP.</i></b> Proteasome inhibitors play a key role in the suppression of the transcription factor NF-B, a downstream component of the BCR signaling pathway that is constitutively activated in ABC-subtype DLBCL<sup><a href="#ref-18">18</a>,<a href="#ref-36">36</a></sup>. A landmark study showed that bortezomib sensitized and enhanced the activity of chemotherapy in ABC-subtype DLBCL<sup><a href="#ref-37">37</a></sup>. The study showed that bortezomib combined with DA-EPOCH in relapse/refractory DLBCL yielded a CR of 18% and a PR of 16% and demonstrated a significantly higher response rate (83% versus 13%, P&lt;0.001) and median OS (10.8 versus 3.4 months, P=0.003) in ABC DLBCL compared to GCB DLBCL, respectively<sup><a href="#ref-37">37</a></sup>. However, two recent phase II trials (LYM-2034 trial and PYRAMID trial) comparing bortezomib plus R-CAP or bortezomib plus R-CHOP versus R-CHOP in newly diagnosed non-GCB-subtype DLBCL have failed to show improved efficacy in terms of ORR and PFS<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. Offner <i>et al</i>. demonstrated that there were no significant differences between bortezomib plus R-CAP and R-CHOP in CR rate (64% versus 66%, OR 0.91, P=0.80), ORR (93% versus 99%, OR 0.21, P=0.11), PFS (HR 1.12, P=0.76), or OS (HR 0.89, P=0.75)<sup><a href="#ref-38">38</a></sup>. Leonardo <i>et al</i>. also showed that there were no significant differences between bortezomib plus R-CHOP and R-CHOP in 2-year estimates of PFS (82% versus 78%, P=0.61) and OS (93% versus 88%, P=0.76)<sup><a href="#ref-39">39</a></sup>. However, further clinical trials may not be precluded by these results: in the LYM-2034 trial, the chemotherapy dose intensity was suboptimal in the bortezomib plus R-CAP arm, and in the PYRAMID trial, the outcomes of the R-CHOP arm were better than expected considering the non-GCB subtype. In addition, both trials are performed based on IHC-based, but not GEP-based, COO assignment. These factors should be considered when we interpret the results of the LYM-2034 and PYRAMID trials. Preliminary results of a randomized, double-blind, phase III trial (REMoDL-B trial) comparing bortezomib plus R-CHOP versus R-CHOP in newly diagnosed ABC-subtype DLBCL defined by central GEP assay (DASL) showed no difference in PFS of ABC-subtype and GCB-subtype patients (2-year PFS 71%)<sup><a href="#ref-40">40</a></sup>. This study indicates that bortezomib may help to overcome the poor prognosis of ABC-subtype DLBCL. The REMoDL-B trial is still awaiting the 30-month follow-up and the final results are pending.</p></div><div class=section><a name=d71867e509 class=n-a></a><h3 class=section-title>Double-hit DLBCL</h3><p class="" id=d71867e514>Double-hit lymphomas (DHLs) are a heterogeneous group of mature B-cell lymphomas that harbor rearrangements of MYC and BCL2. However, MYC/BCL6 DHLs or MYC/BCL2/BCL6 triple-hit lymphomas can also occur<sup><a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. The majority of DHL cases fall into the categories of DLBCL or B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma. Virtually all double-hit DLBCLs are GCB subtype. Double-hit DLBCL showed a very aggressive clinical course and had a dismal prognosis when treated with standard R-CHOP treatment<sup><a href="#ref-43">43</a></sup>. Notably, DHLs or triple-hit lymphomas are classified in the new category of high-grade B-cell lymphoma (HGBL), with rearrangements of MYC and BCL2 and/or BCL6 in the 2016 updated WHO classification<sup><a href="#ref-44">44</a></sup>. Double-expresser lymphomas are defined based on IHC stains with MYC and BCL2 staining in more than a specified proportion of tumor cells. Most double-expresser DLBCLs are found within the ABC subtype of DLBCL. Double-expresser DLBCL also has an inferior outcome compared with classical DLBCL and has an intermediate outcome between double-hit DLBCL and classical DLBCL<sup><a href="#ref-43">43</a>,<a href="#ref-45">45</a><a href="#ref-47">47</a></sup>. However, we should interpret these results with caution owing to the retrospective nature of these data.</p><p class="" id=d71867e542><b><i>DA-EPOCH-R.</i></b> Currently, the optimal frontline chemotherapy in double-hit DLBCL is not well defined. Previous retrospective analysis has suggested that DA-EPOCH-R could be a viable option in double-hit DLBCL because it improved ORR and PFS compared with R-CHOP<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. Recently, Howlett <i>et al</i>. reported a meta-analysis comparing R-CHOP, DA-EPOCH-R, and dose-intensive (DI) regimens (R-Hyper-CVAD and R-CODOX-M/IVAC). They showed that the median PFS for the R-CHOP (n=180), R-EPOCH (n=91), and DI (n=123) groups were 12.1, 22.2, and 18.9 months, respectively. First-line treatment with R-EPOCH significantly reduced the risk of progression compared with R-CHOP treatment<sup><a href="#ref-50">50</a></sup>. Promising preliminary results have been reported for a phase II study (NCT01092182) of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphomas, which showed that the PFS, TTP, and OS were 79%, 86%, and 77%, respectively, at a median follow-up of 14 months<sup><a href="#ref-51">51</a></sup>. Further analysis of these data with longer follow-up is planned.</p><p class="" id=d71867e566><b><i>Novel agents.</i></b> The two major strategies for novel agents in DHLs are 1) modulating the transcription of MYC, BCL2, or BCL6 and 2) targeting MYC, BCL2, or BCL6 proteins. For modulation of the transcription of MYC, BCL2, or BCL6, epigenetics-based treatment with diverse BET bromodomain inhibitors may show promise (BAY1238097 [NCT02369029], CPI-0610 [NCT01949883], OTX015 [NCT01713582], and JQ1)<sup><a href="#ref-43">43</a></sup>. For targeting the proteins, BCL2 inhibitors (navitoclax and venetoclax) and a MYC-targeting aurora A kinase inhibitor (alisertib) show promise and warrant further evaluation<sup><a href="#ref-43">43</a>,<a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d71867e590>Conclusions</h2><p class="" id=d71867e593>We are at the threshold of an era of precision therapy for DLBCL, of which subtype-specific therapy would be the first step. Ongoing trials may in the near future change the current chemotherapy backbone R-CHOP and provide strategies for using combinations of novel agents with the chemotherapy backbone according to the molecular subtypes of DLBCL defined by GEP assay.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d71867e599>Abbreviations</h2><p class="" id=d71867e602>ABC, activated B-cell; BTK, Brutons tyrosine kinase; CI, confidence interval; COO, cell-of-origin; CR, complete response; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab; DASL, cDNA-mediated annealing, selection, extension, and ligation; DHL, double-hit lymphoma; DI, dose intensive; DLBCL, diffuse large B-cell lymphoma; DSHNHL, Deutsche Studiengruppe Hochmaligne Non-Hodgkin Lymphome; EFS, event-free survival; FFPET, formalin-fixed paraffin-embedded tissue; GCB, germinal center B-cell; GEP, gene expression profiling; G-CHOP, obinutuzumab, cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; IHC, immunohistochemistry; IPI, international prognostic index; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PMB, primary mediastinal B-cell; PR, partial response; R-ACVBP, rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; TTP, time to progression</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d71867e1 class=n-a></a><h2 class=main-title id=d72039>Competing interests</h2><p class=metadata-entry><a name=d71867e111 class=n-a></a><p id=d71867e113> All authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d71867e1 class=n-a></a><h2 class=main-title id=d72041>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d71867e609 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d72212>References</h2><div class="section ref-list"><a name=d71867e609 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d71867e616 class=n-a></a>Coiffier B, Lepage E, Briere J, <i> et al.</i>: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med.</i> 2002; <b>346</b>(4): 23542. <a target=xrefwindow id=d71867e627 href="http://www.ncbi.nlm.nih.gov/pubmed/11807147">PubMed Abstract </a> | <a target=xrefwindow id=d71867e630 href="http://dx.doi.org/10.1056/NEJMoa011795">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/14204"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e639 class=n-a></a>Pfreundschuh M, Trmper L, Osterborg A, <i> et al.</i>: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. <i>Lancet Oncol.</i> 2006; <b>7</b>(5): 37991. <a target=xrefwindow id=d71867e650 href="http://www.ncbi.nlm.nih.gov/pubmed/16648042">PubMed Abstract </a> | <a target=xrefwindow id=d71867e653 href="http://dx.doi.org/10.1016/S1470-2045(06)70664-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/14204">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d71867e665 class=n-a></a>Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. <i>Hematology Am Soc Hematol Educ Program.</i> 2011; <b>2011</b>(1): 498505. <a target=xrefwindow id=d71867e673 href="http://www.ncbi.nlm.nih.gov/pubmed/22160081">PubMed Abstract </a> | <a target=xrefwindow id=d71867e676 href="http://dx.doi.org/10.1182/asheducation-2011.1.498">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d71867e685 class=n-a></a>Rcher C, Coiffier B, Haioun C, <i> et al.</i>: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet.</i> 2011; <b>378</b>(9806): 185867. <a target=xrefwindow id=d71867e696 href="http://www.ncbi.nlm.nih.gov/pubmed/22118442">PubMed Abstract </a> | <a target=xrefwindow id=d71867e699 href="http://dx.doi.org/10.1016/S0140-6736(11)61040-4">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1120268"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e708 class=n-a></a>Wilson WH, Dunleavy K, Pittaluga S, <i> et al.</i>: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. <i>J Clin Oncol.</i> 2008; <b>26</b>(16): 271724. <a target=xrefwindow id=d71867e719 href="http://www.ncbi.nlm.nih.gov/pubmed/18378569">PubMed Abstract </a> | <a target=xrefwindow id=d71867e722 href="http://dx.doi.org/10.1200/JCO.2007.13.1391">Publisher Full Text </a> | <a target=xrefwindow id=d71867e726 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2409217">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1120268">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d71867e739 class=n-a></a>Wilson WH, Jung SH, Porcu P, <i> et al.</i>: A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica.</i> 2012; <b>97</b>(5): 75865. <a target=xrefwindow id=d71867e750 href="http://www.ncbi.nlm.nih.gov/pubmed/22133772">PubMed Abstract </a> | <a target=xrefwindow id=d71867e753 href="http://dx.doi.org/10.3324/haematol.2011.056531">Publisher Full Text </a> | <a target=xrefwindow id=d71867e757 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3342980">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725283014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e766 class=n-a></a>Purroy N, Bergua J, Gallur L, <i> et al.</i>: Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>Br J Haematol.</i> 2015; <b>169</b>(2): 18898. <a target=xrefwindow id=d71867e777 href="http://www.ncbi.nlm.nih.gov/pubmed/25521006">PubMed Abstract </a> | <a target=xrefwindow id=d71867e780 href="http://dx.doi.org/10.1111/bjh.13273">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725283014">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718449500"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e793 class=n-a></a>Murawski N, Pfreundschuh M, Zeynalova S, <i> et al.</i>: Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. <i>Ann Oncol.</i> 2014; <b>25</b>(9): 18006. <a target=xrefwindow id=d71867e804 href="http://www.ncbi.nlm.nih.gov/pubmed/24928834">PubMed Abstract </a> | <a target=xrefwindow id=d71867e807 href="http://dx.doi.org/10.1093/annonc/mdu208">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718449500">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725239845"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e819 class=n-a></a>Pfreundschuh M, Poeschel V, Zeynalova S, <i> et al.</i>: Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. <i>J Clin Oncol.</i> 2014; <b>32</b>(36): 412733. <a target=xrefwindow id=d71867e830 href="http://www.ncbi.nlm.nih.gov/pubmed/25403207">PubMed Abstract </a> | <a target=xrefwindow id=d71867e833 href="http://dx.doi.org/10.1200/JCO.2013.54.6861">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725239845">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d71867e846 class=n-a></a>Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL. <i>Clin Adv Hematol Oncol.</i> 2014; <b>12</b>(8 Suppl 16): 89. <a target=xrefwindow id=d71867e854 href="http://www.ncbi.nlm.nih.gov/pubmed/25768993">PubMed Abstract </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725449781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e863 class=n-a></a>Jaeger U, Trneny M, Melzer H, <i> et al.</i>: Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica.</i> 2015; <b>100</b>(7): 95563. <a target=xrefwindow id=d71867e874 href="http://www.ncbi.nlm.nih.gov/pubmed/25911553">PubMed Abstract </a> | <a target=xrefwindow id=d71867e877 href="http://dx.doi.org/10.3324/haematol.2015.125344">Publisher Full Text </a> | <a target=xrefwindow id=d71867e881 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4486230">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725449781">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d71867e895 class=n-a></a>Salles GA, Morschhauser F, Solal-Cligny P, <i> et al.</i>: Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. <i>J Clin Oncol.</i> 2013; <b>31</b>(23): 29206. <a target=xrefwindow id=d71867e906 href="http://www.ncbi.nlm.nih.gov/pubmed/23835715">PubMed Abstract </a> | <a target=xrefwindow id=d71867e909 href="http://dx.doi.org/10.1200/JCO.2012.46.9718">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718028213"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e918 class=n-a></a>Morschhauser FA, Cartron G, Thieblemont C, <i> et al.</i>: Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. <i>J Clin Oncol.</i> 2013; <b>31</b>(23): 29129. <a target=xrefwindow id=d71867e929 href="http://www.ncbi.nlm.nih.gov/pubmed/23835718">PubMed Abstract </a> | <a target=xrefwindow id=d71867e932 href="http://dx.doi.org/10.1200/JCO.2012.46.9585">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718028213">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d71867e944 class=n-a></a>Zelenetz AD, Mobasher M, Costa LJ, <i> et al.</i>: Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). <i>Blood.</i> 2013; <b>122</b>(21): 1820. <a target=xrefwindow id=d71867e955 href="http://www.bloodjournal.org/content/122/21/1820">Reference Source</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1001595"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e964 class=n-a></a>Alizadeh AA, Eisen MB, Davis RE, <i> et al.</i>: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. <i>Nature.</i> 2000; <b>403</b>(6769): 50311. <a target=xrefwindow id=d71867e975 href="http://www.ncbi.nlm.nih.gov/pubmed/10676951">PubMed Abstract </a> | <a target=xrefwindow id=d71867e978 href="http://dx.doi.org/10.1038/35000501">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1001595">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1148287"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e991 class=n-a></a>Lenz G, Wright G, Dave SS, <i> et al.</i>: Stromal gene signatures in large-B-cell lymphomas. <i>N Engl J Med.</i> 2008; <b>359</b>(22): 231323. <a target=xrefwindow id=d71867e1002 href="http://www.ncbi.nlm.nih.gov/pubmed/19038878">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1005 href="http://dx.doi.org/10.1056/NEJMoa0802885">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1148287">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718173957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1018 class=n-a></a>Roschewski M, Staudt LM, Wilson WH: Diffuse large B-cell lymphoma-treatment approaches in the molecular era. <i>Nat Rev Clin Oncol.</i> 2014; <b>11</b>(1): 1223. <a target=xrefwindow id=d71867e1026 href="http://www.ncbi.nlm.nih.gov/pubmed/24217204">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1029 href="http://dx.doi.org/10.1038/nrclinonc.2013.197">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718173957">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725516148"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1042 class=n-a></a>Scott DW: Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? <i>Am Soc Clin Oncol Educ Book.</i> 2015; e45866. <a target=xrefwindow id=d71867e1047 href="http://www.ncbi.nlm.nih.gov/pubmed/25993210">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1050 href="http://dx.doi.org/10.14694/EdBook_AM.2015.35.e458">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725516148">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d71867e1062 class=n-a></a>Hans CP, Weisenburger DD, Greiner TC, <i> et al.</i>: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood.</i> 2004; <b>103</b>(1): 27582. <a target=xrefwindow id=d71867e1073 href="http://www.ncbi.nlm.nih.gov/pubmed/14504078">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1076 href="http://dx.doi.org/10.1182/blood-2003-05-1545">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/10182959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1085 class=n-a></a>Gutirrez-Garca G, Cardesa-Salzmann T, Climent F, <i> et al.</i>: Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood.</i> 2011; <b>117</b>(18): 483643. <a target=xrefwindow id=d71867e1096 href="http://www.ncbi.nlm.nih.gov/pubmed/21441466">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1099 href="http://dx.doi.org/10.1182/blood-2010-12-322362">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/10182959">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d71867e1112 class=n-a></a>Barrans SL, Crouch S, Care MA, <i> et al.</i>: Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. <i>Br J Haematol.</i> 2012; <b>159</b>(4): 44153. <a target=xrefwindow id=d71867e1123 href="http://www.ncbi.nlm.nih.gov/pubmed/22970711">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1126 href="http://dx.doi.org/10.1111/bjh.12045">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d71867e1135 class=n-a></a>Veldman-Jones MH, Lai Z, Wappett M, <i> et al.</i>: Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System. <i>Clin Cancer Res.</i> 2015; <b>21</b>(10): 236778. <a target=xrefwindow id=d71867e1146 href="http://www.ncbi.nlm.nih.gov/pubmed/25301847">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1149 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-0357">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718231014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1158 class=n-a></a>Scott DW, Wright GW, Williams PM, <i> et al.</i>: Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood.</i> 2014; <b>123</b>(8): 12147. <a target=xrefwindow id=d71867e1169 href="http://www.ncbi.nlm.nih.gov/pubmed/24398326">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1172 href="http://dx.doi.org/10.1182/blood-2013-11-536433">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3931191">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718231014">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725696264"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1190 class=n-a></a>Scott DW, Mottok A, Ennishi D, <i> et al.</i>: Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>J Clin Oncol.</i> 2015; <b>33</b>(26): 284856. <a target=xrefwindow id=d71867e1201 href="http://www.ncbi.nlm.nih.gov/pubmed/26240231">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1204 href="http://dx.doi.org/10.1200/JCO.2014.60.2383">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1208 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4554747">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725696264">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d71867e1221 class=n-a></a>Rimsza LM, Wright G, Schwartz M, <i> et al.</i>: Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. <i>Clin Cancer Res.</i> 2011; <b>17</b>(11): 372732. <a target=xrefwindow id=d71867e1232 href="http://www.ncbi.nlm.nih.gov/pubmed/21364035">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1235 href="http://dx.doi.org/10.1158/1078-0432.CCR-10-2573">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1239 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3107869">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d71867e1248 class=n-a></a>Collie AM, Nolling J, Divakar KM, <i> et al.</i>: Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex<sup></sup> system. <i>Br J Haematol.</i> 2014; <b>167</b>(2): 2815. <a target=xrefwindow id=d71867e1262 href="http://www.ncbi.nlm.nih.gov/pubmed/24961756">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1266 href="http://dx.doi.org/10.1111/bjh.12983">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1269 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4188713">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d71867e1278 class=n-a></a>Mareschal S, Ruminy P, Bagacean C, <i> et al.</i>: Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. <i>J Mol Diagn.</i> 2015; <b>17</b>(3): 273283. <a target=xrefwindow id=d71867e1289 href="http://www.ncbi.nlm.nih.gov/pubmed/25891505">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1292 href="http://dx.doi.org/10.1016/j.jmoldx.2015.01.007">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d71867e1301 class=n-a></a>Xue X, Zeng N, Gao Z, <i> et al.</i>: Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR. <i>Lab Invest.</i> 2015; <b>95</b>(1): 11320. <a target=xrefwindow id=d71867e1312 href="http://www.ncbi.nlm.nih.gov/pubmed/25418578">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1315 href="http://dx.doi.org/10.1038/labinvest.2014.136">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d71867e1324 class=n-a></a>Choi MY, Kipps TJ: Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. <i>Cancer J.</i> 2012; <b>18</b>(5): 40410. <a target=xrefwindow id=d71867e1332 href="http://www.ncbi.nlm.nih.gov/pubmed/23006944">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1335 href="http://dx.doi.org/10.1097/PPO.0b013e31826c5810">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1338 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3461329">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725658391"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1348 class=n-a></a>Wilson WH, Young RM, Schmitz R, <i> et al.</i>: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nat Med.</i> 2015; <b>21</b>(8): 9226. <a target=xrefwindow id=d71867e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/26193343">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1362 href="http://dx.doi.org/10.1038/nm.3884">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725658391">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718499066"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1375 class=n-a></a>Younes A, Thieblemont C, Morschhauser F, <i> et al.</i>: Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncol.</i> 2014; <b>15</b>(9): 101926. <a target=xrefwindow id=d71867e1386 href="http://www.ncbi.nlm.nih.gov/pubmed/25042202">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1389 href="http://dx.doi.org/10.1016/S1470-2045(14)70311-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718499066">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725662420"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1402 class=n-a></a>Gribben JG, Fowler N, Morschhauser F: Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. <i>J Clin Oncol.</i> 2015; <b>33</b>(25): 280311. <a target=xrefwindow id=d71867e1410 href="http://www.ncbi.nlm.nih.gov/pubmed/26195701">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1413 href="http://dx.doi.org/10.1200/JCO.2014.59.5363">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725662420">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/717948533"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1426 class=n-a></a>Yang Y, Shaffer AL 3rd, Emre NC, <i> et al.</i>: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. <i>Cancer Cell.</i> 2012; <b>21</b>(6): 72337. <a target=xrefwindow id=d71867e1437 href="http://www.ncbi.nlm.nih.gov/pubmed/22698399">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1440 href="http://dx.doi.org/10.1016/j.ccr.2012.05.024">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1444 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4059833">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/717948533">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718389157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1457 class=n-a></a>Vitolo U, Chiappella A, Franceschetti S, <i> et al.</i>: Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(7): 7307. <a target=xrefwindow id=d71867e1468 href="http://www.ncbi.nlm.nih.gov/pubmed/24831981">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1471 href="http://dx.doi.org/10.1016/S1470-2045(14)70191-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718389157">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718537515"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1484 class=n-a></a>Nowakowski GS, LaPlant B, Macon WR, <i> et al.</i>: Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. <i>J Clin Oncol.</i> 2015; <b>33</b>(3): 2517. <a target=xrefwindow id=d71867e1495 href="http://www.ncbi.nlm.nih.gov/pubmed/25135992">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1498 href="http://dx.doi.org/10.1200/JCO.2014.55.5714">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718537515">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725508570"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1512 class=n-a></a>Nowakowski GS, Czuczman MS: ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? <i>Am Soc Clin Oncol Educ Book.</i> 2015; e44957. <a target=xrefwindow id=d71867e1517 href="http://www.ncbi.nlm.nih.gov/pubmed/25993209">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1520 href="http://dx.doi.org/10.14694/EdBook_AM.2015.35.e449">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725508570">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1161490"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1533 class=n-a></a>Dunleavy K, Pittaluga S, Czuczman MS, <i> et al.</i>: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. <i>Blood.</i> 2009; <b>113</b>(24): 606976. <a target=xrefwindow id=d71867e1544 href="http://www.ncbi.nlm.nih.gov/pubmed/19380866">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1547 href="http://dx.doi.org/10.1182/blood-2009-01-199679">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1551 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2699229">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1161490">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725690867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1564 class=n-a></a>Offner F, Samoilova O, Osmanov E, <i> et al.</i>: Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. <i>Blood.</i> 2015; <b>126</b>(16): 1893901. <a target=xrefwindow id=d71867e1575 href="http://www.ncbi.nlm.nih.gov/pubmed/26232170">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1578 href="http://dx.doi.org/10.1182/blood-2015-03-632430">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4616024">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725690867">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d71867e1595 class=n-a></a>Randomized Phase 2 Open-Label Study of R-CHOP  Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918). <i>Clin Adv Hematol Oncol.</i> 2016; <b>14</b>(2 Suppl 1): 156. <a target=xrefwindow id=d71867e1603 href="http://www.ncbi.nlm.nih.gov/pubmed/27007007">PubMed Abstract </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d71867e1612 class=n-a></a>Davies AJ, Caddy J, Maishman T, <i> et al.</i>: A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). <i>Blood.</i> 2015; <b>126</b>. <a target=xrefwindow id=d71867e1623 href="https://ash.confex.com/ash/2015/webprogram/Paper86301.html">Reference Source</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d71867e1632 class=n-a></a>Dunleavy K: Double-hit lymphomas: current paradigms and novel treatment approaches. <i>Hematology Am Soc Hematol Educ Program.</i> 2014; <b>2014</b>(1): 10712. <a target=xrefwindow id=d71867e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/25696842">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1643 href="http://dx.doi.org/10.1182/asheducation-2014.1.107">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/4428956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1653 class=n-a></a>Barrans S, Crouch S, Smith A, <i> et al.</i>: Rearrangement of <i>MYC</i> is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. <i>J Clin Oncol.</i> 2010; <b>28</b>(20): 33605. <a target=xrefwindow id=d71867e1667 href="http://www.ncbi.nlm.nih.gov/pubmed/20498406">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1671 href="http://dx.doi.org/10.1200/JCO.2009.26.3947">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/4428956">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d71867e1684 class=n-a></a>Sarkozy C, Traverse-Glehen A, Coiffier B: Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. <i>Lancet Oncol.</i> 2015; <b>16</b>(15): e55567. <a target=xrefwindow id=d71867e1692 href="http://www.ncbi.nlm.nih.gov/pubmed/26545844">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1695 href="http://dx.doi.org/10.1016/S1470-2045(15)00005-4">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d71867e1704 class=n-a></a>Swerdlow SH, Campo E, Pileri SA, <i> et al.</i>: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood.</i> 2016; <b>127</b>(20): 237590. <a target=xrefwindow id=d71867e1715 href="http://www.ncbi.nlm.nih.gov/pubmed/26980727">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1718 href="http://dx.doi.org/10.1182/blood-2016-01-643569">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4874220">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d71867e1731 class=n-a></a>Johnson NA, Slack GW, Savage KJ, <i> et al.</i>: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>J Clin Oncol.</i> 2012; <b>30</b>(28): 34529. <a target=xrefwindow id=d71867e1742 href="http://www.ncbi.nlm.nih.gov/pubmed/22851565">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1745 href="http://dx.doi.org/10.1200/JCO.2011.41.0985">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3454768">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d71867e1758 class=n-a></a>Horn H, Ziepert M, Becher C, <i> et al.</i>: MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. <i>Blood.</i> 2013; <b>121</b>(12): 225363. <a target=xrefwindow id=d71867e1769 href="http://www.ncbi.nlm.nih.gov/pubmed/23335369">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1772 href="http://dx.doi.org/10.1182/blood-2012-06-435842">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d71867e1781 class=n-a></a>Hu S, Xu-Monette ZY, Tzankov A, <i> et al.</i>: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood.</i> 2013; <b>121</b>(20): 402131; quiz 4250. <a target=xrefwindow id=d71867e1792 href="http://www.ncbi.nlm.nih.gov/pubmed/23449635">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1795 href="http://dx.doi.org/10.1182/blood-2012-10-460063">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1799 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3709650">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718457660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1809 class=n-a></a>Oki Y, Noorani M, Lin P, <i> et al.</i>: Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>Br J Haematol.</i> 2014; <b>166</b>(6): 891901. <a target=xrefwindow id=d71867e1820 href="http://www.ncbi.nlm.nih.gov/pubmed/24943107">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1823 href="http://dx.doi.org/10.1111/bjh.12982">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718457660">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/723347673"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1836 class=n-a></a>Petrich AM, Gandhi M, Jovanovic B, <i> et al.</i>: Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood.</i> 2014; <b>124</b>(15): 235461. <a target=xrefwindow id=d71867e1847 href="http://www.ncbi.nlm.nih.gov/pubmed/25161267">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1850 href="http://dx.doi.org/10.1182/blood-2014-05-578963">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/723347673">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725449189"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1863 class=n-a></a>Howlett C, Snedecor SJ, Landsburg DJ, <i> et al.</i>: Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. <i>Br J Haematol.</i> 2015; <b>170</b>(4): 50414. <a target=xrefwindow id=d71867e1874 href="http://www.ncbi.nlm.nih.gov/pubmed/25907897">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1877 href="http://dx.doi.org/10.1111/bjh.13463">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725449189">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d71867e1890 class=n-a></a>Dunleavy K, Fanale M, LaCasce A, <i> et al.</i>: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. <i>Blood</i> 2014; <b>124</b>(21): 395. <a target=xrefwindow id=d71867e1901 href="http://www.bloodjournal.org/content/124/21/395">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d71867e1910 class=n-a></a>Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. <i>Clin Adv Hematol Oncol.</i> 2014; <b>12</b>(8 Suppl 16): 189. <a target=xrefwindow id=d71867e1918 href="http://www.ncbi.nlm.nih.gov/pubmed/25768998">PubMed Abstract </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718112987"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d71867e1927 class=n-a></a>Friedberg JW, Mahadevan D, Cebula E, <i> et al.</i>: Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. <i>J Clin Oncol.</i> 2014; <b>32</b>(1): 4450. <a target=xrefwindow id=d71867e1938 href="http://www.ncbi.nlm.nih.gov/pubmed/24043741">PubMed Abstract </a> | <a target=xrefwindow id=d71867e1941 href="http://dx.doi.org/10.1200/JCO.2012.46.8793">Publisher Full Text </a> | <a target=xrefwindow id=d71867e1945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3867644">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718112987">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-1933.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-1933.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Oncology, Asan Medical Centre, University of Ulsan, Seoul, 05505, South Korea<br/> <sup>2</sup> Division of Hematology-Oncology, Department of Medicine, Samsung Medical Centre, Sungkyunkwan University, Seoul, 135-710, South Korea<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-1933/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 08 Aug 2016, 5:1933 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.8790.1">https://doi.org/10.12688/f1000research.8790.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2016 Hong JY <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=9460 data-id=8790 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8790.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-1933/v1/pdf?article_uuid=21acf028-966b-4baf-9a51-51a6ff45d3c5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.8790.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Hong JY, Suh C and Kim WS. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):1933 (<a href="https://doi.org/10.12688/f1000research.8790.1" target=_blank>https://doi.org/10.12688/f1000research.8790.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=8790 id=mobile-track-article-signin-8790 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8790?target=/articles/5-1933.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=9460 /> <input name=articleId type=hidden value=8790 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Randy Gascoyne</strong>, Department of Pathology & Laboratory Medicine, University of British Columbia, British Columbia Cancer Agency, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Randy Gascoyne is an inventor of the assay, and NanoString has taken out a license on the patent. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Mark Roschewski</strong>, Lymphoma Therapeutics Section, Metabolism Branch, National Cancer Institute, NIH, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-1933.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-1933.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=9545-15548></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16474-15549></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-1933/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>08 Aug 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Randy Gascoyne</strong>, Department of Pathology & Laboratory Medicine, University of British Columbia, British Columbia Cancer Agency, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Randy Gascoyne is an inventor of the assay, and NanoString has taken out a license on the patent. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Mark Roschewski</strong>, Lymphoma Therapeutics Section, Metabolism Branch, National Cancer Institute, NIH, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-1933.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-1933/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Evolution of frontline treatment of diffuse...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-1933/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-1933/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-1933/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Hong JY et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-1933/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-1933",
            templates : {
                twitter : "Evolution of frontline treatment of diffuse large B-cell lymphoma:.... Hong JY et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-1933/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/8790/9460")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "9460");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15548": 0,
                           "15549": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "da9c069b-325a-4603-b919-db6842cd675a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1933.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1933.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-1933.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-1933.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-1933.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>